New York Times: A Dearth in Innovation for Key Drugs
Eduardo Porter, New York Times columnist

“…Antibiotics face a daunting proposition. They are not only becoming more difficult to develop, but they are also not obviously profitable. … Research on new antibiotics could be encouraged by allowing shorter clinical trials for the promising molecules or guaranteeing minimum returns for groundbreaking drugs. … At the same time, new mechanisms are needed to constrain prices…” (7/22).